Gebremariam Teclegiorgis, Alkhazraji Sondus, Baldin Clara, Kovanda Laura, Wiederhold Nathan P, Ibrahim Ashraf S
Division of Infectious Diseases, Los Angeles Biomedical Research Institute at Harbor-University of California Los Angeles (UCLA) Medical Center and St. John's Cardiovascular Research Center, Torrance, California, USA.
Astellas Pharma Global Development, Inc., Northbrook, Illinois, USA.
Antimicrob Agents Chemother. 2017 Apr 24;61(5). doi: 10.1128/AAC.02589-16. Print 2017 May.
We assessed prophylactic or continuous therapy of isavuconazole, posaconazole, or voriconazole in treating pulmonary murine mucormycosis. In the prophylaxis studies, only isavuconazole treatment resulted in significantly improved survival and lowered tissue fungal burden of immunosuppressed mice infected with In the continuous treatment studies, isavuconazole and posaconazole, but not voriconazole, equally prolonged survival time and lowered tissue fungal burden compared to placebo-treated mice. These results support the use of isavuconazole and posaconazole in prophylaxis treatment.
我们评估了艾沙康唑、泊沙康唑或伏立康唑在治疗小鼠肺部毛霉菌病中的预防性或持续性治疗效果。在预防研究中，只有艾沙康唑治疗可显著提高感染的免疫抑制小鼠的生存率并降低组织真菌负荷。在持续性治疗研究中，与安慰剂治疗的小鼠相比，艾沙康唑和泊沙康唑（而非伏立康唑）同样延长了生存时间并降低了组织真菌负荷。这些结果支持将艾沙康唑和泊沙康唑用于预防性治疗。
